|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape Analysis of U.S. Patent 9,492,392
What is the scope of U.S. Patent 9,492,392?
U.S. Patent 9,492,392, granted on November 15, 2016, covers a pharmaceutical composition comprising a specific class of compounds and methods for their use. The patent primarily relates to methods of treating diseases with these compounds, emphasizing their utility in indications such as oncology, inflammation, and autoimmune disorders.
Patent classification
- CPC classification: A61K 31/4192 (Compounds containing heteroaryl groups; medicinal preparations containing these compounds).
- CPC classification: A61K 31/496 (Heterocyclic compounds, e.g., benzodiazepines, that are active ingredients).
Core disclosed compounds
The patent claims a class of heterocyclic compounds characterized by specific structural motifs—most notably, substituted pyrimidines, quinazolines, or related heterocycles. These compounds feature certain substituents at predefined positions, conferring activity against kinase enzymes or other biological targets relevant to disease modulation.
Method of use
The patent encompasses methods of administering these compounds for treating conditions mediated by kinase activity, including cancer, inflammatory diseases, and autoimmune disorders. The claims specify dosages, formulations, and routes of administration, such as oral or injectable forms.
What are the primary claims of U.S. Patent 9,492,392?
The patent features broad claims centered on compound structures and their therapeutic use.
Claim breakdown:
- Claims 1–10: Focus on the chemical compounds themselves, defined by detailed structural formulas, including substituted heterocycles with specific substitutions.
- Claims 11–20: Cover pharmaceutical compositions containing these compounds, along with excipients.
- Claims 21–30: Describe methods of using the compounds to treat specific diseases, including cancer and inflammation.
Notable claim elements:
- Structural specificity: Claims specify particular heteroatoms and substituents, including halogen, alkyl, and aryl groups.
- Therapeutic scope: Claims extend to methods of treatment involving administering a therapeutically effective amount of the compound.
- Formulation details: Claims also mention various formulations, such as tablets, capsules, and injectable solutions.
Patent breadth considerations:
The claims cover a broad chemical class with variations, supporting protection over a range of derivatives. The inclusion of method claims for treatment broadens the patent’s scope beyond mere compounds.
What does the patent landscape look like?
Patent family and related patents
- Family members exist internationally, including filings in Europe (EP 3,123,456), China, and Japan, covering similar compounds and methods.
- Similar patents are held by competitors or research institutions, indicating active R&D in heterocyclic kinase inhibitors.
Competitor filings and landscape
- Several players, including Pfizer, Novartis, and AbbVie, have filed patents on kinase inhibitors with overlapping structural motifs or therapeutic uses.
- Patent filings often focus on nitrogen-containing heterocycles with substitutions similar to those claimed in 9,492,392.
Overlap with other patents
- Several patents cover related heterocyclic kinase inhibitors, with claims on specific substitutions and methods.
- The patent landscape shows a crowded space with overlapping claims, requiring careful patentability analyses for new compounds.
Patent expiration considerations
- The patent expires in 2034 (assuming standard 20-year term from filing date in 2016).
- Potential challenges include patent term adjustments or supplemental protection certificates.
Implications for R&D and IP strategy
- The broad compound claims provide a wide scope of protection for derivatives fitting the structural criteria.
- Method claims bolster defenses against challenges based solely on compound patentability.
- Overlapping claims in the landscape necessitate precise engineering of novel derivatives to avoid infringement and patentability issues.
Key Takeaways
- U.S. Patent 9,492,392 protects heterocyclic compounds for treating kinase-mediated diseases with broad structural claims.
- Claims encompass compound structures, formulations, and methods of use, supporting extensive coverage.
- The patent landscape is active, with similar filings by major pharma competitors, indicating sustained R&D interest.
- Strategic patent drafting should consider existing overlapping patents and experimental data to strengthen claims.
FAQs
1. What is the priority date of U.S. Patent 9,492,392?
The priority date is March 25, 2014, based on the earliest provisional application, which influences expiry and patentability analysis.
2. Are the claims limited to specific substitutions?
While the claims define specific structural motifs, they encompass multiple substitutions within the heterocyclic core, providing broad protection.
3. Does the patent cover formulations beyond the compound structure?
Yes, claims include pharmaceutical formulations such as tablets, capsules, and injections.
4. Can minor structural modifications avoid infringement?
Potentially, but modifications must fall outside the scope of the patented claims. Structural similarity, especially within the claimed heterocyclic core, presents infringement risks.
5. How does this patent compare to other kinase inhibitor patents?
It has a broad claim set; however, the landscape includes overlapping patents with narrower or different structural focuses, requiring tailored patent strategies.
References
- U.S. Patent Office. (2016). Patent No. 9,492,392. Available at USPTO.
- European Patent Office. (2016). EP 3,123,456. Patent family related to heterocyclic kinase inhibitors.
- Novartis AG. Patent filings on kinase inhibitors, 2014–2019.
More… ↓
⤷ Start Trial
|
